Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Assembly Biosciences (ASMB)

Assembly Biosciences (ASMB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 464,545
  • Shares Outstanding, K 15,817
  • Annual Sales, $ 28,520 K
  • Annual Income, $ -40,180 K
  • EBIT $ -43 M
  • EBITDA $ -47 M
  • 60-Month Beta 1.14
  • Price/Sales 6.80
  • Price/Cash Flow N/A
  • Price/Book 2.59

Options Overview Details

View History
  • Implied Volatility 101.31% (-13.22%)
  • Historical Volatility 57.51%
  • IV Percentile 30%
  • IV Rank 31.62%
  • IV High 165.07% on 09/17/25
  • IV Low 71.82% on 10/20/25
  • Expected Move (DTE 34) 0.00 (0.00%)
  • Put/Call Vol Ratio 2.00
  • Today's Volume 3
  • Volume Avg (30-Day) 17
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 310
  • Open Int (30-Day) 261
  • Expected Range 29.37 to 29.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.51
  • Number of Estimates 1
  • High Estimate -0.51
  • Low Estimate -0.51
  • Prior Year -1.57
  • Growth Rate Est. (year over year) +67.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.16 +0.72%
on 01/16/26
38.99 -24.67%
on 12/22/25
-4.13 (-12.33%)
since 12/16/25
3-Month
27.07 +8.50%
on 10/22/25
39.71 -26.03%
on 11/20/25
+0.29 (+1.00%)
since 10/16/25
52-Week
7.75 +278.97%
on 04/07/25
39.71 -26.03%
on 11/20/25
+14.95 (+103.68%)
since 01/16/25

Most Recent Stories

More News
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes

– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years –

ASMB : 29.37 (-1.81%)
GILD : 124.91 (+3.01%)
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion...

– 98% reduction in HSV-2 shedding rate, >99% reduction in high viral load shedding rate and 91% reduction in virologically confirmed genital lesion rate observed in 50 mg weekly oral dose of ABI-1179,...

ASMB : 29.37 (-1.81%)
Assembly Biosciences: Q3 Earnings Snapshot

Assembly Biosciences: Q3 Earnings Snapshot

ASMB : 29.37 (-1.81%)
Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates

– Released positive Phase 1b interim results for long-acting helicase-primase inhibitor candidate ABI-5366 showing significant reductions in viral shedding rate and genital lesion rate in recurrent genital...

ASMB : 29.37 (-1.81%)
Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®

– Phase 1b data demonstrating favorable safety and tolerability profile and potent reductions in viral nucleic acids highlighted in late-breaking poster presentation – SOUTH SAN FRANCISCO, Calif.,...

ASMB : 29.37 (-1.81%)
Assembly Biosciences Announces Upcoming Investor Conference Participation

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases,...

ASMB : 29.37 (-1.81%)
Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe

– Late-breaking oral presentation highlights interim Phase 1b data reported earlier this year for two cohorts in participants with recurrent genital herpes –  – Statistically significant reductions...

ASMB : 29.37 (-1.81%)
Assembly Biosciences Announces Pricing of $175 Million in Equity Financings

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (“Assembly Bio”) (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious...

ASMB : 29.37 (-1.81%)
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes

– 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort evaluating 350 mg weekly oral dose compared to placebo over...

ASMB : 29.37 (-1.81%)
Assembly Biosciences: Q2 Earnings Snapshot

Assembly Biosciences: Q2 Earnings Snapshot

ASMB : 29.37 (-1.81%)

Business Summary

Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for...

See More

Key Turning Points

3rd Resistance Point 31.27
2nd Resistance Point 30.80
1st Resistance Point 30.09
Last Price 29.37
1st Support Level 28.91
2nd Support Level 28.44
3rd Support Level 27.73

See More

52-Week High 39.71
Last Price 29.37
Fibonacci 61.8% 27.50
Fibonacci 50% 23.73
Fibonacci 38.2% 19.96
52-Week Low 7.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar